Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072787 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer
A Phase 1 study, sponsored by Taiho Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT00072787 is a Phase 1 study that has completed, run by Taiho Oncology. The registered enrollment target is 41 participants.
The verdict
NCT00072787, a Phase 1 study, has completed, sponsored by Taiho Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of the phase 1 portion of the study is to determine the safe dose of S-1 and cisplatin that can be administered in gastric cancer patients. The purpose of the phase 2 portion of the study is to determine the antitumor activity of the S-1 and cisplatin regimen established from phase 1 in patients with advanced gastric cancer.
Interventions
- DRUG cisplatin
- DRUG S-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072787
The ClinicalTrials.gov registry entry for NCT00072787 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cisplatin is the first listed.
NCT00072787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00072787 about?
NCT00072787 is a clinical study titled "Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer". The purpose of the phase 1 portion of the study is to determine the safe dose of S-1 and cisplatin that can be administered in gastric cancer patients. The purpose of the phase 2 portion of the study is to determine the antitumor activity of the S-1 and cisplatin regimen established from phase 1 in...
What is the current status of trial NCT00072787?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2003-10. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00072787?
The interventions under investigation include: cisplatin (DRUG), S-1 (DRUG).
Who is sponsoring clinical trial NCT00072787?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.